Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia, according to Roche. Data from multiple studies have ...

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for a kind of ...

The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie ...

Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia. Roche Holding AG RHHBY announced new data from the phase III MURANO ...

AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the Cancer Drugs Fund. The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England ...

The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who ...

- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to ...

AbbVie has presented new data showing the potential of Venclyxto (venetoclax) to reduce the risk of death in previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for ...

(RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...